source
- Amylyx reports Phase 3 success for avexitide in post-bariatric hypoglycemiaAmylyx announced a late-stage success for avexitide, a GLP-1 receptor antagonist, in a Phase 3 trial targeting post-bariatric hypoglycemia. The trial results showed the drug achieved its primary e…
- Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 millionLeo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight. Under the deal, Leo Pharm…